PDE5-IN-13
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active.
For research use only. We do not sell to patients.
- Formula: C31H26N4O2
- Molecular Weight:486.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
PDE5A 3 nM (IC50) |
PDE1C 10478 nM (IC50) |
PDE2A 3378 nM (IC50) |
PDE3A >100000 nM (IC50) |
PDE4D2 53294 nM (IC50) |
PDE6C 20 nM (IC50) |
PDE7A 25746 nM (IC50) |
PDE8A1 >100000 nM (IC50) |
PDE9A2 >100000 nM (IC50) |
PDE10A2 21160 nM (IC50) |
PDE11A >100000 nM (IC50) |
In Vitro
The C3-cyanide group of PDE5-IN-13 forms hydrogen bond bridges with D764 and H613 through water molecules, which stabilizes the binding conformation of PDE5-IN-13[1].
The [1-(pyridin-2-yl)ethyl] amino side chain at C8-position of PDE5-IN-13 is located near the solvent-exposed region, and the hydrophilic pyridine ring can interact with the solvent region, enhancing inhibitory affinity of PDE5-IN-13[1].
PDE5-IN-13 inhibitor displays weak inhibition against the CYP1A2, CYP2D6, and CYP3A4 with IC50s above 50 μM, and for CYP2C19 and CYP2C9 is 4.63 and 9.76 μM, respectively[1].
PDE5-IN-13 exhibits much weaker inhibitory activity toward hERG channel with an IC50 above 30 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
PDE5-IN-13 (5.0 mg/kg, p.o., daily, 21 days) shows a remarkable increase in mPAP (pulmonary arterial pressure) and decrease in RVHI (right ventricular hypertrophy index) than Sildenafil citrate (HY-15025A) (10.0 mg/kg) in a Monocrotaline (HY-N0750)-induced PAH rat model[1].
In Vivo Pharmacokinetic Properties of PDE-IN-5
| PK Parameters | i.v. Administration (2 mg/kg) | p.o. Administration (10 mg/kg) |
| aAUC(0-t) (ng/mL・h) | 398.9 | 338.8 |
| AUC(0−∞) (ng/mL・h) | 399.0 | 340.5 |
| AUC(0−t) (h) | 0.75 | 6.3 |
| AUC(0−∞) (h) | 0.76 | 6.4 |
| t1/2 (h) | 2.25 | 2.79 |
| Tmax (h) | 0.083 | 4.0 |
| CL (L/h/kg) | 5.0 | 31.5 |
| Vz (L/kg) | 16.3 | 126.6 |
| Cmax (ng/mL) | 985.2 | 58.4 |
| F (%) | 16.8 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 486.56
-
Formula C31H26N4O2
-
SMILES
C[C@@H](NC1=CC=CC(C(C2=CC=C(OC)C=C2)=C3C#N)=C1N(CC4=CC=CC=C4)C3=O)C5=CC=CC=N5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PDE5-IN-13 Related Classifications
HY-170435 Related Classifications
Powered by Bioz